When its comes to business in Brazil, Ranbaxy has many firsts to its credit. It claims to be the first Indian Company to get its plants approved by the regulatory authorities of Brazil. It is considered as the first company from Asia to get its Generic dosage forms approved by Ministry of Health, Brazil. It is also the first Indian company to market its Bio-equivalent Generics in Brazil.
With a sales of over US $ 31 million, Ranbaxy is the largest foreign generics pharmaceutical MNC in Brazil. It is ranked amongst the top five generic companies in the country. Ranbaxy is gearing up for better performance in Brazil and is in the process of setting up a new state-of-the-art manufacturing plant in Sao Gonzalo near Rio de Janeiro.
Ranbaxy's entry into Brazil market was in 2000, through its majority-owned entity - Ranbaxy SP Medicamentos Ltd. Five years down the line, the company's sales (in Jan-Dec 2004) touched US$ 31 Mn, up by 37% over that of the previous year. A total of ten new generic molecules and three new-branded products were launched during the year 2004. The company gained much due to the improved market share of two of its key branded products Isotretinoin & Cecnoin. The company increased its branded product portfolio last year with the launch of Contiflo (Tamsulosin) and Cutison (Mometasone). With this, the total number of brands introduced in this market is five. The new manufacturing facility is expected to meet the growing demand of Brazil and the neighboring markets.
As on date, Ranbaxy has received 31 regulatory approvals from Brazilian drug authority. It has made 12 regulatory filings in the country during January-December 2004. The company has also filed three international DMFs in Brazil during the period. It also got three DMFs approved in 2004.
Interestingly, 2003 was one of the most productive periods for Ranbaxy as the company had registered 21 products in Brazil. , Twelve of these were commercialized the same year, as most of the approvals received from National Agencia de Vigilancia Sanitaria (ANVISA) were towards the last quarter of 2003. Simvastatin, Amoxy-Clav, Levofloxacin, Norfloxacin and Lisinopril were the major selling products. An expanded Quality Testing Laboratory was also established during the year, leading to in-house testing of all the products marketed, some of which were being outsourced earlier.
The major products of Ranbaxy that are available in Brazilian market are Aciclovir Comp , Amoxcillina+clavulanato de Potassio Amoxicillin Comp 5oomg, Amoxcillina+clavulanato de Potassio Amoxicillin Susp, Amoxicillina Amoxicillin Caps/500mg, Amoxicillina Amoxicillin Susp/250mg.150ml, Amoxicillina Amoxicillin Caps/500mg, Cafaclor Comp Cefadroxil Comp Cefotaxima Sodica Inj/1g/500mg, Ceftriaxona Sodica Ceftrixone Inj/1g/500mg etc.
The BRIC Countries (Brazil; Russia, including Ukraine; India; China) together constitute 26% of the total revenues of Ranbaxy today.